Pfizer's Oral Abroctinib Bests Injectable Dupixent In Atopic Dermatitis Trial
Only top-line data were released by Pfizer, and the safety of abrocitinib, like other JAK inhibitors, could remain an issue.
You may also be interested in...
Sanofi Hits Rare Setback For Dupixent In Urticaria
The French major has hit a rare roadblock in the onward march of its anti-inflammatory blockbuster.
Sanofi Unruffled By JAK Threat To Dupixent
CEO Paul Hudson tells Scrip that in an atopic dermatitis market that has a standard of care like Dupixent, "it's hard to justify the role of a JAK unless somebody has, frankly, failed everything else."
Pfizer And AbbVie JAKs Finally Join Dupixent In US Atopic Dermatitis Space
The arrival on the US eczema market of a couple of oral JAK inhibitors with stellar data on itching could provide a challenge to Sanofi and Regeneron's blockbuster Dupixent. However, Pfizer and AbbVie will have to overcome dermatologists' fears about the class-effect safety warnings their drugs come with.